ROBERT J. CHILTON
The University of Texas at San Antonio Health Science Center · 228 works · 5,484 citations · h-index 35
Top works
- Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
- SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
- Infection of an Implantable Cardioverter Defibrillator: Management Without Removal of the Device in Selected Cases
- Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
- Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
- The Role of Anticoagulation in COVID-19-Induced Hypercoagulability
- Cardiovascular therapy
- The Cardiovascular Effects of GLP‐1 Receptor Agonists
- Angioscopic evaluation of site-specific administration of ReoPro
- GLP-1 agonist-based therapies: An emerging new class of antidiabetic drug with potential cardioprotective effects
- Aortic stiffness: pathophysiology, clinical implications, and approach to treatment
- Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance
- Type 2 diabetes, cardiovascular risk, and the link to insulin resistance
- Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide–1-Based Therapies
- Pathophysiology of coronary heart disease: a brief review.
- PROactive: time for a critical appraisal
- New options for the treatment of obesity and type 2 diabetes mellitus (narrative review)